Pancreatic Cancer Clinical Trials 2023

Browse 99 Pancreatic Cancer Medical Studies Across 307 Cities

8 Phase 3 Trial · 966 Pancreatic Cancer Clinics

Reviewed by Michael Gill, B. Sc.
10 Pancreatic Cancer Clinical Trials Near Me
Top Hospitals for Pancreatic Cancer Clinical Trials
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
9Active Trials
44All Time Trials for Pancreatic Cancer
2006First Pancreatic Cancer Trial
Image of Massachusetts General Hospital in Massachusetts.
Massachusetts General Hospital
Boston
5Active Trials
49All Time Trials for Pancreatic Cancer
1998First Pancreatic Cancer Trial
Image of Dana Farber Cancer Institute in Massachusetts.
Dana Farber Cancer Institute
Boston
5Active Trials
27All Time Trials for Pancreatic Cancer
2006First Pancreatic Cancer Trial
Image of Katmai Oncology Group in Alaska.
Katmai Oncology Group
Anchorage
5Active Trials
12All Time Trials for Pancreatic Cancer
2009First Pancreatic Cancer Trial
Image of Palo Alto Medical Foundation Health Care in California.
Palo Alto Medical Foundation Health Care
Palo Alto
5Active Trials
8All Time Trials for Pancreatic Cancer
2009First Pancreatic Cancer Trial
Top Cities for Pancreatic Cancer Clinical Trials
Image of New York in New York.
New York
27Active Trials
Memorial Sloan Kettering Cancer CenterTop Active Site
Image of Anchorage in Alaska.
Anchorage
26Active Trials
Katmai Oncology GroupTop Active Site
Pancreatic Cancer Clinical Trials by Phase of Trial
N/A Pancreatic Cancer Clinical Trials
8Active Pancreatic Cancer Clinical Trials
8Number of Unique Treatments
4Number of Active Locations
Pancreatic Cancer Clinical Trials by Age GroupMost Recent Pancreatic Cancer Clinical TrialsTop Treatments for Pancreatic Cancer Clinical Trials
Treatment Name
Active Pancreatic Cancer Clinical Trials
All Time Trials for Pancreatic Cancer
First Recorded Pancreatic Cancer Trial
Treatment
13
13
1998
Gemcitabine
2
248
1998
Pharmacological Study
2
15
2007
Gemcitabine Hydrochloride
2
21
2003
Chemotherapy
2
14
2009
Recently Completed Studies with FDA Approved Treatments for Pancreatic Cancer
Treatment
Year
Sponsor
Cisplatin
2021
CanBas Co. Ltd.
Dapagliflozin
2021
Washington University School of Medicine
Plerixafor
2020
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dostarlimab
2020
Massachusetts General Hospital
MVT-5873
2019
National Cancer Institute (NCI)
Nivolumab
2019
University of California, Davis
TRPV6 Calcium Channel Inhibitor SOR-C13
2019
M.D. Anderson Cancer Center
Liposomal Irinotecan
2019
Washington University School of Medicine
V941
2019
Merck Sharp & Dohme Corp.
nivolumab
2019
National Cancer Institute (NCI)

What Are Pancreatic Cancer Clinical Trials?

Pancreatic cancer clinical trials seek to test new drugs or treatment protocols for pancreatic cancer patients. If it is diagnosed early, pancreatic cancer is treatable; however, there are no discernable symptoms in the early stages, so it's rarely detected.

Symptoms only start to appear as the disease spreads to other organs, by which time it is a more advanced stage and at which time treatment options are limited.

Trials are aimed at both early detection and treatment.

What Is Pancreatic Cancer?

The pancreas organ is located behind the lower part of the stomach. The pancreas releases enzymes that aid digestion and produce and release hormones that help control the body's sugar levels.

Pancreatic cancer is observed when a metastatic tumor forms in the pancreatic cells. There are two main categories of pancreatic cancer.

  1. Pancreatic exocrine tumors.
  2. Pancreatic neuroendocrine tumors.

What Are Clinical Trials For Pancreatic Cancer?

Pancreatic cancer trials aim to test the best treatment options and give participating patients early access to cutting-edge treatment. They intend to advance progress and provide treatment with better outcomes.

Why Is Pancreatic Cancer Being Studied Through Clinical Trials?

Over 62,000 Americans are diagnosed with pancreatic cancer annually, and just under 50,000 Americans will die from the disease. It accounts for 3% of all cancers in America and 7% of all cancer deaths.

The five-year survival rate of pancreatic cancer is 10%.

Clinical trials are run to find better treatments with improved outcomes, and treatments used were the subject of previous clinical trials.

What Are The Types of Treatments Available For Pancreatic Cancer?

Current treatments for early-stage pancreatic cancer include surgery, radiation, and chemotherapy. There is no viable treatment for late-stage Pancreatic cancer.

Examples Of Current Pancreatic Treatment Trials Are

PV-10 (10% Rose Bengal Disodium) For Pancreatic Metastatic Cancer

This trial tests a single treatment injection of the drug PV-10 intended for patients with inoperable cancer.The trial will measure the drug's efficacy, safety, and the body's tolerance.

Plerixafor For Pancreatic Metastatic Cancer

The trial tests a new cancer treatment combination for safety and effectiveness in people with pancreatic cancer that has spread.

Improving Early Detection

The trial, conducted by the Pancreatic Cancer Cohort Consortium, piggybacks off the new-onset diabetes tests. The tests have shown that that 1 in 100 people with new-onset diabetes are also diagnosed with pancreatic cancer within 3 years.

The trials comprises of two imaging studies which use computerized tomography (CT) scans or magnetic resonance imaging (MRI) and their efficacy as early Detection of Pancreatic Ductal Adenocarcinoma on patients who have tested positive for hyperglycemia and diabetes.

What Are Some Recent Breakthrough Clinical Trials For Pancreatic Cancer?

Pancreatic clinical trials look to help prevent, detect, and treat pancreatic cancer,

2013: Testing The Efficacy of a second-line regimen treatment - A study, conducted by the CONKO Study Group, was performed to test the use of oxaliplatin and folinic acid-modulated fluorouracil on patients with advanced pancreatic cancer. The conclusion of the trial was that the treatments extended the duration of overall survival.

2023: Improved outcome – A study, conducted by the Perelman School of Medicine at the University of Pennsylvania, found that trial participants who received the immunotherapy nivolumab with two chemotherapy drugs, nab-paclitaxel, and gemcitabine, have an increased first-year survival rate from 35% to 57.7%.

Who Are Some Of The Key Opinion Leaders / Researchers In Pancreatic Cancer Research?

Dr. Brian Wolpin is the Director of the Gastrointestinal Cancer Center and Co-Director of the Pancreas and Biliary Tumor Center at Dana-Farber

Jason Fleming, MD: Moffitt Cancer Center in Tampa, FL

Andrea Wang-Gillam, MD Ph.D.: Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 10th, 2021

Last Reviewed: August 21st, 2023

References1 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. Review. https://pubmed.ncbi.nlm.nih.gov/314019032 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. https://pubmed.ncbi.nlm.nih.gov/314019033 Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O(2)(⋅-) and H(2)O(2)-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268. https://pubmed.ncbi.nlm.nih.gov/283666794 Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75. doi: 10.1007/s00280-013-2070-8. Epub 2013 Feb 5. https://pubmed.ncbi.nlm.nih.gov/233818145 Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum In: Cancer Cell. 2017 Aug 14;32(2):268. https://pubmed.ncbi.nlm.nih.gov/283666796 Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75. doi: 10.1007/s00280-013-2070-8. Epub 2013 Feb 5. https://pubmed.ncbi.nlm.nih.gov/233818147 Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, Taghiyev AF, Du C, Knudson CM, Cullen JJ. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res. 2010 Jan 15;16(2):509-20. doi: 10.1158/1078-0432.CCR-09-1713. Epub 2010 Jan 12. https://pubmed.ncbi.nlm.nih.gov/200680728 Ugolkov AV, Bondarenko GI, Dubrovskyi O, Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ, Giles FJ, Mazar AP. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724. doi: 10.1097/CAD.0000000000000652. https://pubmed.ncbi.nlm.nih.gov/298462509 Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F, O'Halloran T, Cryns VL, Mazar AP. GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Lett. 2016 Oct 1;380(2):384-392. doi: 10.1016/j.canlet.2016.07.006. Epub 2016 Jul 14. https://pubmed.ncbi.nlm.nih.gov/2742428910 Pal K, Cao Y, Gaisina IN, Bhattacharya S, Dutta SK, Wang E, Gunosewoyo H, Kozikowski AP, Billadeau DD, Mukhopadhyay D. Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer. Mol Cancer Ther. 2014 Feb;13(2):285-96. doi: 10.1158/1535-7163.MCT-13-0681. Epub 2013 Dec 10. https://pubmed.ncbi.nlm.nih.gov/24327518